Prognostic and tumor immunity implication of inflammatory bowel disease-associated genes in colorectal cancer

Eur J Med Res. 2022 Jun 13;27(1):91. doi: 10.1186/s40001-022-00720-0.

Abstract

Background: Epidemiologic studies continue to emphasize that increasing patients with inflammatory bowel disease (IBD) develop to colorectal cancer (CRC). Although the function and mechanisms of IBD-associated genes (IBDGs) in CRC tumorigenesis have been extensively researched, the implications of IBDGs in the prognosis value and tumor immunity of CRC remain unclear.

Results: In this study, the expression, pathological stages and prognostic value of IBDGs in CRC were systematically analyzed, and 7 prognostic genes including CDH1, CCL11, HLA-DRA, NOS2, NAT2, TIMP1 and TP53 were screened through LASSO-Cox regression analysis. Then, a prognostic signature was established based on the 7 prognostic genes, and the model exhibited a good ability in risk stratification of CRC patients. Subsequent results showed that the genetic alterations of the 7 prognostic genes exhibited more significant and extensive influence on immune cells infiltration in colon adenocarcinoma than that in rectal adenocarcinoma. Meanwhile, immune cells infiltration also showed a significant difference between low-risk group and high-risk group. What's more, 7 prognostic genes-based risk stratification was associated with microsatellite instability, and its prognostic characteristics were significantly negatively correlated with mismatch repair genes.

Conclusions: This study provided a promising insight that the 7 IBDGs could be used as valuable biomarkers for prognostic diagnosis and personalized immunotherapy of CRC patients.

Keywords: Biomarkers; Colorectal cancer; IBD-associated genes; Immune cells infiltration; Prognostic signature.

MeSH terms

  • Adenocarcinoma*
  • Arylamine N-Acetyltransferase*
  • Biomarkers, Tumor / genetics
  • Colonic Neoplasms*
  • Colorectal Neoplasms* / pathology
  • Humans
  • Inflammatory Bowel Diseases* / complications
  • Inflammatory Bowel Diseases* / genetics
  • Prognosis

Substances

  • Biomarkers, Tumor
  • Arylamine N-Acetyltransferase
  • NAT2 protein, human